214 related articles for article (PubMed ID: 29870915)
1. Combination and inducible adjuvants targeting nucleic acid sensors.
Temizoz B; Kuroda E; Ishii KJ
Curr Opin Pharmacol; 2018 Aug; 41():104-113. PubMed ID: 29870915
[TBL] [Abstract][Full Text] [Related]
2. Targeting Cytosolic Nucleic Acid-Sensing Pathways for Cancer Immunotherapies.
Iurescia S; Fioretti D; Rinaldi M
Front Immunol; 2018; 9():711. PubMed ID: 29686682
[TBL] [Abstract][Full Text] [Related]
3. Detection of Microbial Infections Through Innate Immune Sensing of Nucleic Acids.
Tan X; Sun L; Chen J; Chen ZJ
Annu Rev Microbiol; 2018 Sep; 72():447-478. PubMed ID: 30200854
[TBL] [Abstract][Full Text] [Related]
4. Antiinfective applications of toll-like receptor 9 agonists.
Krieg AM
Proc Am Thorac Soc; 2007 Jul; 4(3):289-94. PubMed ID: 17607015
[TBL] [Abstract][Full Text] [Related]
5. Nucleic Acid Sensing Machinery: Targeting Innate Immune System for Cancer Therapy.
Iurescia S; Fioretti D; Rinaldi M
Recent Pat Anticancer Drug Discov; 2018; 13(1):2-17. PubMed ID: 29086701
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists.
Vollmer J; Krieg AM
Adv Drug Deliv Rev; 2009 Mar; 61(3):195-204. PubMed ID: 19211030
[TBL] [Abstract][Full Text] [Related]
7. The future of toll-like receptor therapeutics.
Parkinson T
Curr Opin Mol Ther; 2008 Feb; 10(1):21-31. PubMed ID: 18228178
[TBL] [Abstract][Full Text] [Related]
8. TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN.
Temizoz B; Kuroda E; Ohata K; Jounai N; Ozasa K; Kobiyama K; Aoshi T; Ishii KJ
Eur J Immunol; 2015 Apr; 45(4):1159-69. PubMed ID: 25529558
[TBL] [Abstract][Full Text] [Related]
9. Innate immune sensing and signaling of cytosolic nucleic acids.
Wu J; Chen ZJ
Annu Rev Immunol; 2014; 32():461-88. PubMed ID: 24655297
[TBL] [Abstract][Full Text] [Related]
10. TLR9 agonists as adjuvants for prophylactic and therapeutic vaccines.
Daubenberger CA
Curr Opin Mol Ther; 2007 Feb; 9(1):45-52. PubMed ID: 17330401
[TBL] [Abstract][Full Text] [Related]
11. New adjuvants for human vaccines.
Mbow ML; De Gregorio E; Valiante NM; Rappuoli R
Curr Opin Immunol; 2010 Jun; 22(3):411-6. PubMed ID: 20466528
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulators as adjuvants for vaccines and antimicrobial therapy.
Nicholls EF; Madera L; Hancock RE
Ann N Y Acad Sci; 2010 Dec; 1213():46-61. PubMed ID: 20946578
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy with STING and TLR9 agonists promotes synergistic therapeutic efficacy with suppressed cancer-associated fibroblasts in colon carcinoma.
Hajiabadi S; Alidadi S; Montakhab Farahi Z; Ghahramani Seno MM; Farzin H; Haghparast A
Front Immunol; 2023; 14():1258691. PubMed ID: 37901237
[TBL] [Abstract][Full Text] [Related]
14. Type I interferons as vaccine adjuvants against infectious diseases and cancer.
Bracci L; La Sorsa V; Belardelli F; Proietti E
Expert Rev Vaccines; 2008 Apr; 7(3):373-81. PubMed ID: 18393607
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor immunity by transcriptional synergy between TLR9 and STING activation.
Temizoz B; Hioki K; Kobari S; Jounai N; Kusakabe T; Lee MSJ; Coban C; Kuroda E; Ishii KJ
Int Immunol; 2022 Jul; 34(7):353-364. PubMed ID: 35419609
[TBL] [Abstract][Full Text] [Related]
16. [Development of Nucleic Acid-Based Adjuvant for Cancer Immunotherapy].
Kobiyama K; Ishii KJ
Gan To Kagaku Ryoho; 2015 Sep; 42(9):1040-5. PubMed ID: 26469159
[TBL] [Abstract][Full Text] [Related]
17. The STING controlled cytosolic-DNA activated innate immune pathway and microbial disease.
Konno H; Barber GN
Microbes Infect; 2014 Dec; 16(12):998-1001. PubMed ID: 25449752
[TBL] [Abstract][Full Text] [Related]
18. Innate sensors that regulate vaccine responses.
Georg P; Sander LE
Curr Opin Immunol; 2019 Aug; 59():31-41. PubMed ID: 30978666
[TBL] [Abstract][Full Text] [Related]
19. Innate immune control of nucleic acid-based vaccine immunogenicity.
Koyama S; Coban C; Aoshi T; Horii T; Akira S; Ishii KJ
Expert Rev Vaccines; 2009 Aug; 8(8):1099-107. PubMed ID: 19627190
[TBL] [Abstract][Full Text] [Related]
20. Encapsulation of two different TLR ligands into liposomes confer protective immunity and prevent tumor development.
Bayyurt B; Tincer G; Almacioglu K; Alpdundar E; Gursel M; Gursel I
J Control Release; 2017 Feb; 247():134-144. PubMed ID: 28069554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
